<code id='AB38769DA3'></code><style id='AB38769DA3'></style>
    • <acronym id='AB38769DA3'></acronym>
      <center id='AB38769DA3'><center id='AB38769DA3'><tfoot id='AB38769DA3'></tfoot></center><abbr id='AB38769DA3'><dir id='AB38769DA3'><tfoot id='AB38769DA3'></tfoot><noframes id='AB38769DA3'>

    • <optgroup id='AB38769DA3'><strike id='AB38769DA3'><sup id='AB38769DA3'></sup></strike><code id='AB38769DA3'></code></optgroup>
        1. <b id='AB38769DA3'><label id='AB38769DA3'><select id='AB38769DA3'><dt id='AB38769DA3'><span id='AB38769DA3'></span></dt></select></label></b><u id='AB38769DA3'></u>
          <i id='AB38769DA3'><strike id='AB38769DA3'><tt id='AB38769DA3'><pre id='AB38769DA3'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:hotspot    Page View:937
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more
          Liver decline slowed by off
          Liver decline slowed by off

          AdobeWASHINGTON—TherearethreeFDA-approveddrugsfortreatingalcoholusedisorder.Butadifferentmedication,

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          For longer

          MarianF.MoratinosforSTATEnticedbytheimmensemarketopenedbyGLP-1weightlossdrugsWegovyandZepbound,ahand